MX385276B - Tratamiento para la enfermedad de parkinson - Google Patents

Tratamiento para la enfermedad de parkinson

Info

Publication number
MX385276B
MX385276B MX2018014944A MX2018014944A MX385276B MX 385276 B MX385276 B MX 385276B MX 2018014944 A MX2018014944 A MX 2018014944A MX 2018014944 A MX2018014944 A MX 2018014944A MX 385276 B MX385276 B MX 385276B
Authority
MX
Mexico
Prior art keywords
alkyl
haloalkyl
hydrogen
disease
parkinson
Prior art date
Application number
MX2018014944A
Other languages
English (en)
Spanish (es)
Other versions
MX2018014944A (es
Inventor
Gajanan Uttamrao Chidrewar
Manoj Atmaramji Upadhya
Nitin Krishnaji Damle
Prabal Sengupta
Sameer Vishwanath Mehetre
Sanjay Nandlalji Mandhane
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MX2018014944A publication Critical patent/MX2018014944A/es
Publication of MX385276B publication Critical patent/MX385276B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018014944A 2016-06-02 2017-06-02 Tratamiento para la enfermedad de parkinson MX385276B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621019185 2016-06-02
IN201621019087 2016-06-02
PCT/IN2017/050224 WO2017208267A1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease

Publications (2)

Publication Number Publication Date
MX2018014944A MX2018014944A (es) 2019-03-07
MX385276B true MX385276B (es) 2025-03-18

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014944A MX385276B (es) 2016-06-02 2017-06-02 Tratamiento para la enfermedad de parkinson

Country Status (26)

Country Link
US (4) US10849887B2 (OSRAM)
EP (2) EP3463351B1 (OSRAM)
JP (1) JP6974357B2 (OSRAM)
KR (1) KR102508288B1 (OSRAM)
CN (1) CN109475539B (OSRAM)
AU (1) AU2017273415B2 (OSRAM)
CL (1) CL2018003431A1 (OSRAM)
CY (1) CY1125285T1 (OSRAM)
DK (1) DK3463351T3 (OSRAM)
ES (1) ES2914782T3 (OSRAM)
HR (1) HRP20220683T1 (OSRAM)
HU (1) HUE059387T2 (OSRAM)
IL (1) IL263188B (OSRAM)
LT (1) LT3463351T (OSRAM)
MX (1) MX385276B (OSRAM)
MY (1) MY193754A (OSRAM)
NZ (1) NZ748592A (OSRAM)
PH (1) PH12018502457B1 (OSRAM)
PL (1) PL3463351T3 (OSRAM)
PT (1) PT3463351T (OSRAM)
RS (1) RS63243B1 (OSRAM)
SG (1) SG11201810294QA (OSRAM)
SI (1) SI3463351T1 (OSRAM)
SM (1) SMT202200228T1 (OSRAM)
UA (1) UA123018C2 (OSRAM)
WO (1) WO2017208267A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013166295A1 (en) 2012-05-02 2013-11-07 Georgetown University Treating neural disease with tyrosine kinase inhibitors
EP3463351B1 (en) 2016-06-02 2022-04-27 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
CA3120639A1 (en) 2018-11-20 2020-05-28 Georgetown University Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
BR112021024835A2 (pt) * 2019-06-11 2022-01-18 Sun Pharma Advanced Res Co Ltd Tratamento para sinuclenopatias
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
JP2023536440A (ja) 2020-07-31 2023-08-25 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド アルツハイマー病の治療のためのn’-(2-クロロ-6-メチルベンゾイル)-4-メチル-3-[2-(3-キノリル)エチニル]-ベンゾヒドラジド
CA3251516A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Methods of reducing progression of neurodegenerative disease
KR20250040552A (ko) 2023-09-14 2025-03-24 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103502217B (zh) * 2011-01-21 2015-11-25 太阳医药高级研究有限公司 包含酪氨酸激酶抑制剂的二芳基乙炔酰肼
WO2013166295A1 (en) 2012-05-02 2013-11-07 Georgetown University Treating neural disease with tyrosine kinase inhibitors
EA032697B1 (ru) * 2015-05-18 2019-07-31 Сан Фарма Адвансед Ресёрч Компани Лимитед Амидогетероарилароилгидразидэтины
EP3463351B1 (en) * 2016-06-02 2022-04-27 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease

Also Published As

Publication number Publication date
HUE059387T2 (hu) 2022-11-28
AU2017273415B2 (en) 2023-01-19
IL263188B (en) 2021-08-31
MY193754A (en) 2022-10-27
CN109475539B (zh) 2021-12-28
SMT202200228T1 (it) 2022-07-21
DK3463351T3 (da) 2022-06-07
EP3463351A1 (en) 2019-04-10
US20240066014A1 (en) 2024-02-29
US20210015805A1 (en) 2021-01-21
NZ748592A (en) 2025-11-28
JP6974357B2 (ja) 2021-12-01
AU2017273415A1 (en) 2018-12-06
US11583522B2 (en) 2023-02-21
PH12018502457B1 (en) 2022-01-12
CY1125285T1 (el) 2025-03-28
LT3463351T (lt) 2022-06-10
SI3463351T1 (sl) 2022-07-29
BR112018074439A2 (pt) 2019-03-06
PL3463351T3 (pl) 2022-06-20
CL2018003431A1 (es) 2019-05-10
JP2019520344A (ja) 2019-07-18
EP4085912A1 (en) 2022-11-09
WO2017208267A1 (en) 2017-12-07
PH12018502457A1 (en) 2019-10-21
CN109475539A (zh) 2019-03-15
PT3463351T (pt) 2022-06-02
KR20190015257A (ko) 2019-02-13
US11813252B2 (en) 2023-11-14
MX2018014944A (es) 2019-03-07
RS63243B1 (sr) 2022-06-30
SG11201810294QA (en) 2018-12-28
UA123018C2 (uk) 2021-02-03
CA3024976A1 (en) 2017-12-07
US20190275017A1 (en) 2019-09-12
KR102508288B1 (ko) 2023-03-09
US10849887B2 (en) 2020-12-01
US20220273632A1 (en) 2022-09-01
ES2914782T3 (es) 2022-06-16
EP3463351B1 (en) 2022-04-27
HRP20220683T1 (hr) 2022-07-08
IL263188A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
MX385276B (es) Tratamiento para la enfermedad de parkinson
MX2020000261A (es) Nuevos compuestos.
CR20180022A (es) Derivados etinilo.
MX379474B (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR095823A1 (es) Compuesto de ciclopropanamina y uso del mismo
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
AR091285A1 (es) Inhibidores de bromodominio y sus usos
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
PE20140934A1 (es) Derivados de pirazol
UY36257A (es) “compuestos de imidazopiridazina”.
PE20240930A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
AR099047A1 (es) Derivados etinilo
AR081821A1 (es) Antranilamidas sustituidas con triazol como plaguicidas
UY31824A (es) Nuevos compuestos
CU20100252A7 (es) Derivados de dibenzotiazepina
UY37641A (es) Compuestos de isoxazol carboxamida y usos de los mismos
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
MX345264B (es) Derivado de azol.